Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease | Eli Lilly and Company  Investors | Eli Lilly and Company

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *